UPDATE 1-Novartis copycat product takes aim at Amgen's Enbrel
October 02, 2015 at 02:12 AM EDT
ZURICH, Oct 2 (Reuters) - The U.S. Food and Drug Administration has accepted Novartis AG unit Sandoz's regulatory submission for approval of a biosimilar to Amgen Inc's blockbuster Enbrel drug, the Swiss drugmaker said on Friday.
